69 pages •
By Infiniti Research Limited
• Nov 2015
Strong net sales in aortic and peripheral products with the addition of a part of Covidien' s peripheral business, and growth in cardiac rhythm & heartfailure and coronary and structural heart categories attributed to the growth of the revenue.
Lingering concerns have been hanging over AstraZeneca’s Onglyza and Takeda’s Nesina since 2013 when detailed analyses from respective cardiovascular (CV) outcomes studies suggested the DPP-IV inhibitors may be associated with an increased risk of heartfailure.